Getinge


Q2 25: Margin surprise lifts shares

21/07/25 -"Getinge’s Q2 2025 profit exceeded estimates. Organic sales increased by 4.1%, and order intake rose by 4.4%, despite nominal declines due to currency effects. Adjusted EBITA increased by 0.8% ..."

Pages
64
Language
English
Published on
21/07/25
You may also be interested by these reports :
22/07/25
Sartorius reported a 5.7% revenue growth in Q2 2025, primarily driven by a 7.8% increase in Bioprocess Solutions, which offset a 2.6% decline in Lab ...

22/07/25
Since our analysis of family-owned in-vitro diagnostics specialist BioMerieux’s (Add; France) investment case in July 2023, there has been a notable ...

21/07/25
Getinge’s Q2 2025 profit exceeded estimates. Organic sales increased by 4.1%, and order intake rose by 4.4%, despite nominal declines due to currency ...

17/07/25
The reported FY2024-25 numbers fell short of our expectations due to higher-than-anticipated operating and other financial expenses. In the near ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO